Semaglutide vs. Tirzepatide: How to Choose the Right GLP-1
Semaglutide and tirzepatide are both GLP-1 based therapies, but they differ in mechanism and average results. Here is how clinicians weigh the choice.
Semaglutide acts on the GLP-1 receptor alone, while tirzepatide acts on both GLP-1 and GIP receptors. In trials, tirzepatide produced greater average weight loss (around 20%) than semaglutide (around 15%), but the right choice depends on your health history, tolerance, and goals as assessed by a clinician.
The core difference
Semaglutide is a single-receptor (GLP-1) agonist. Tirzepatide is a dual agonist, activating both GLP-1 and GIP receptors, which may explain its larger average effect on weight in head-to-head data.
Average results
Across pivotal trials, semaglutide averaged about 15% body-weight reduction and tirzepatide about 20-22%. These are averages; many factors shift individual outcomes.
Tolerability
Both share a similar gastrointestinal side-effect profile. Some patients tolerate one better than the other, which is why titration and clinician follow-up matter.
How clinicians choose
A prescriber weighs your starting weight, medical history, prior medication response, and goals. There is no universally superior option; there is a right fit for each person.
Sources
Frias JP et al., Tirzepatide versus Semaglutide Once Weekly, NEJM 2021.
Frequently asked questions
Is tirzepatide always better than semaglutide?
Not necessarily. Tirzepatide showed larger average weight loss in trials, but the best option depends on your history and tolerance.
Can you switch between them?
Switching is possible under clinician guidance, typically with a fresh titration schedule.